Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices
Harold Thibodeaux, Research Investigator
Coming soon.. Please contact customer care for new schedule
||Course "Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion.
The mission of the Food and Drug Administration is “Protecting consumers and enhancing public health by maximizing compliance of FDA regulated products and minimizing risk associated with those products.”
The Food and Drug Administration’s Center for Drug Evaluation Research, Center for Biologics Evaluation Research and Center for Devices and Radiological Health are responsible for the approval of drug products, biologics and medical devices in their respective industries.
This seminar will outline the structural role of the FDA and a brief introduction to the Food, Drug and Cosmetic Act (the ACT) and how the FDA uses it to enforce the regulatory requirements during the drug, biologics and medical device approval process.
Additionally, this seminar will highlight safety, which is in the FDA’s mission statement, by guiding participants on how to develop a data safety monitoring plan and when it is important to use a Data Safety Monitoring Board. Additionally, various safety management practices will be discussed and the importance of creating a functional adverse event database.
This seminar will also provide the terminology necessary to establish an adverse event monitoring score and the training requirements for study monitors will be discussed in detail. IND and IDE safety reports, IND annual safety updates and Development Safety Update Report (DSUR) will be discussed. Additionally, the best approach on how to discuss safety events with clinical site principal investigators to correct reporting issues. During the life of a clinical trial, several FDA audits are possible, therefore, an organized plan to have in place on how to survive an FDA audit for safety management practices will complete the agenda for this seminar.
Upon completing this course on the "Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices" participants will:
- Have a knowledge of the role, structure what the Food and Drug Administration (FDA) regulates
- Learn the importance of the Food, Drug and Cosmetic Act (FDCA)
- Learn how to setup a data safety monitoring plan and when to use a data safety monitoring board
- Learn the various safety management practices employed during clinical studies
- Understand the importance of the training requirements of safety monitors (investigators)
- Discuss how to create an adverse event database
- Learn the submitting process for IND/IDE safety reporting
- Understand how to troubleshooting safety events with site principal investigators
- Learn how to survive an FDA audit for safety management practices and what Bioresearch Monitoring
Seminar Fee Includes:
USB with seminar presentation
Hard copy of presentation
$100 Gift Cert for next seminar
Who will Benefit
This course is designed for people tasked with developing drug products, biologics and medical devices; and responsible for overseeing a company's clinical development program and regulatory strategies. This includes individuals responsible for overseeing regulatory affairs, developing strategies for establishing data safety monitoring plans, establishing adverse event databases, submitting timely safety reports to comply with regulatory compliance and those tasked with ensuring corporate compliance. Among others, this includes:
- Quality managers
- Quality professionals
- Regulatory professionals
- Compliance professionals
- Medical device professionals
- Biotechnology and pharmaceutical professionals
- Clinical Investigators
- Study Monitors
- Quality auditors
- Data analysis specialist
- Document control specialists
- Record retention specialists
- Medical affairs
- Marketing Staff
|Day One (8:30 AM – 4:30 PM)
||Day Two (8:30 AM – 4:30 PM)
Registration Process: 8:30 AM – 9:00 AM
Session Start Time: 9:00 AM
Session 1 (90 Minutes): Introduction to the FDA, Food, Drug and Cosmetic Act – Regulations and Guidance
- Role, Structure and Operations of the FDA
- Good Clinical Practice (GCP) in Clinical Trials
- Regulatory Agencies Involved in Clinical Development of Drug Products
Session 2 (90 Minutes): Establishing and Importance of a Clinical Trial Safety Monitoring Plan
- Data Safety Monitoring Plan (DSMP) and Data Safety Monitoring Boards (DSMB)
- Who Requires What in Clinical Trials
- What is the Best Way to Monitor Your Clinical Trial
- Primary List of the Required Contents of DSMP
Session 3 (90 Minutes): Outline of Various Safety Management Practices Employed in Clinical Trials
- Data Safety Monitoring Boards (What are they and when are they necessary)
- Data Monitoring Committees
- Institutional Review Boards (IRB) and Ethical Review Committees
- Investigator brochure
- Safety Assessment Committees
Session 4 (90 Minutes): The Importance and Training Requirements for Safety Monitors for a Successful Clinical Trial
- General Information about a Clinical Monitor
- Duties in Specific Phases of Clinical Development
- Compliance Training on Good Clinical Practice (GCP), FDA Regulations and Guidelines
- Knowledge Specific to Site Study (SOPs, Protocols, Investigational Product)
- Site Specific Safety Monitoring
Session 5 (90 Minutes): The Process in the Establishment of an Adverse Event Database
- Targeted Data Collection – Recommendations
- Circumstances in Which Targeted Data Collection Maybe Appropriate
- Method for Target or Selection Collection of Safety Data
- When Comprehensive Data Collection is Really Needed
- Types of Data That Should be Collected
Session 1 (90 Minutes): The Procedures and Requirements for Filing and Updating IND Safety Reports
- General Information about Investigational New Drug (IND) and Investigational Device Exemption (IDE)
- Mandatory Safety Reporting (IND – Initial and Follow up Reports)
- Monitoring the Safety Database and Submitting Safety Reports
- Submitting an IND Study
- Safety Reporting for Requirements for BA/BE Studies
- Review of Safety Information
Session 2 (90 Minutes): Comprehensive Discussion on IDE Safety Reports with Medical Devices
- General Information on an Investigational Device Exemption (IDE)
- Mandatory Medical Device Reporting
- Responsibilities of Investigator-Sponsor Safety Reports in Clinical Trials
- Reporting Requirements for Manufacturers
- Reporting Requirements for Investigators
- MedSun: Shining a Light on Medical Products Safety
Session 3 (90 Minutes): Safety Reporting for IND Annual Safety Update and Development Safety Update Report (DSUR)
- General Principles
- Relationship of DSUR to the Periodicity Safety Update Report
- Durations of DSUR Submissions
- Responsibilities for Preparing and Submitting a DSUR
- Guidance on Contents of a DSUR
- Significant Findings from Clinical Trials During the Reporting Periods
Session 4 (90 Minutes): Troubleshooting Safety Events with Site Principle Investigators to Ensure Study Quality
- Background Information – FDA Guidance
- Overview of Clinical Investigator Responsibilities
- Supervision of the conduct of the Clinical Investigator
- Protecting the Rights, Safety and Welfare of Study Subjects
- Reporting Timeframes
- Types of Reportable Events
- Protocol Deviation – Major and Minor ones.
Session 5 (90 Minutes): How to Prepare for an FDA Audit for Safety Management Practices
- Discuss legal obligations of FDA audits and Food Drug and Cosmetic Act
- Suggestion as to the steps clinical sites take to prepare for the FDA Inspector
- Bioresearch Monitoring or BIMO Inspection
- What is Form FDA 482?
- FDA inspection procedures
- Post-inspection procedures and importance of Form FDA 483
Meet Your Instructor
Harold Thibodeaux is a medical research scientist with in vivo pharmacological experiences in both academia and biopharmaceutical industry. During his prestigious career the focus of Mr. Thibodeaux’s research efforts has been on the efficacy of cardiovascular drugs most notably Hypertension, Myocardial Infarction, Focal Ischemia (Stroke), Beyond Advair Pulmonary Research and topical antibiotics. Optimal therapeutic benefits were the goal in all of these projects but cardiovascular safety to provide safer medicines to patients was a priority. Mr. Thibodeaux transitioned into the pharmaceutical industry when he joined the Cardiovascular Department of Genentech in 1990, as a technical lead with the Second Generation TPA Project Team. Mr. Thibodeaux is a graduate from the College of Charleston with a Bachelor of Science Degree in biology and is a member of The Safety Pharmacology Society.
During his prestigious career, Harold Thibodeaux’s ambition and innovation resulted in the successful clinical development of several novel drugs. As a young scientist with Genentech, his contributions to the Second Generation TPA Project were rewarded with the FDA approval of a thrombolytic drug (TNK-TPA or Tenectaplase) that was indicated for Acute Myocardial Infarction. Another notable achievement with the same project team was the approval of Activase Alterplase for Acute Ischemic Stroke Treatment.
As a scientist at Theravance, his innovative models of cardiovascular safety were instrumental in the formation of a Theravance/GlaxoSmithKline Partnership and the development of two clinical candidates for Chronic Obstructive Pulmonary Disease (COPD). Both drugs, BREO Ellipta and ANORO Ellipta, were approved by the FDA and are currently providing therapeutic benefits with patients with COPD.
In his role as an investigative scientist with Stiefel, a GlaxoSmithKline Company, Mr. Thibodeaux explored new medical research paths and using his many years of experience in the industry to support project efforts for the reformulations of topical antibiotics, development of models to study acne and writing protocols psoriasis.
During his years of academia and pharmaceutical industry provided an opportunity to authored 23 published articles and discussed his work with poster presentation at major scientific meetings. Harold is proud to have been a medical researcher in both academia and the biopharmaceutical industry and continues to support projects that lead to strategic partnerships that will develop novel drug pipelines for unmet medical needs and present webinars and seminars on drug development to assist pharmaceutical companies achieve their goals.
Register by P.O. / Check
Yes, I want to attend "Best Practices for Safety Reporting in Clinical Trials for Drugs, Biologics and Medical Devices".
Click here to download P.O. form
If you are paying by check:
Checks should be payable to MetricStream Inc. (our parent company) and mailed to:
2479 East Bayshore Road
Palo Alto, CA 94303
Send your team for maximum benefit.
Get your team up to speed!
Significant tuition discounts are available for teams of two or more from the same company. You must register at the same time and provide a single payment to take advantage of the discount.
||Get 10% off
|3 to 6 Attendees
||Get 20% off
|7 to 10 Attendees
||Get 25% off
||Get 30% off
Call toll free on +1-888-717-2436 if you have any queries.
Register by Wire Transfer
If you wish to pay by wire transfer, please call us toll free on +1-888-717-2436
Terms & Conditions to Register for the Seminar/Conference/Event
Your registration for the seminar is subject to following terms and conditions. If you need any clarification before registering for this seminar please call us @ +1-888-717-2436 or email us @ firstname.lastname@example.org
Payment is required 2 days before the date of the conference. We accept American Express, Visa and MasterCard. Make checks payable to MetricStream Inc. (our parent company).
Cancellations and substitutions:
Written cancellations through fax or email (from the person who has registered for this conference) received at least 10 calendar days prior to the start date of the event will receive a refund — less a $200 administration fee. No cancellations will be accepted — nor refunds issued — within 10 calendar days before the start date of the event.
On request by email or fax (before the seminar) a credit for the amount paid minus administration fees ($200) will be transferred to any future ComplianceOnline event and a credit note will be issued.
Substitutions may be made at any time. No-shows will be charged the full amount.
We discourage onsite registrations, however if you wish to register onsite, payment to happen through credit card immediately or check to be submitted onsite. Conference material will be given on the spot if it is available after distributing to other attendees. In case it is not available, we will send the material after the conference is over.
In the event ComplianceOnline cancels the seminar, ComplianceOnline is not responsible for any airfare, hotel, other costs or losses incurred by registrants. Some topics and speakers may be subject to change without notice.
Attendance confirmation and documents to carry to the seminar venue:
After we receive the payment from the registered attendee, an electronic event pass will be sent to the email address associated with the registrant 5 working days before the seminar date. Please bring the pass to the venue of the event.
Conference photograph / video:
By registering and attending ComplianceOnline conference, you agree to have your photographs or videos taken at the conference venue and you do not have any objections to ComplianceOnline using these photos and videos for marketing, archiving or any other conference related activities. You agree to release ComplianceOnline from any kind of claims arising out of copyright or privacy violations.
If you wish to partner with us for this event
contact us: email@example.com
call us: +1-888-717-2436.
Media Partner Benefits
- Logo and company data on the event website.
- Logo on the conference material distributed during the conference.
- Media partner’s brochure distributed along with conference material.
- Logo on all the mailings before and after the event.
- 10% discount to media partner's subscribers.
Media Partner To Do
- Banner (min 728x90 or 468x60) on the media partner website.
- Insertion of the event in the event calendar, both printed and/or online.
- Announcement article of the conference on the magazine and/or website.
- Dedicated email blast to media partner’s subscribers.
- Article on the magazine and/or website after the conference.
If you wish to sponsor this event
contact Cruise Webster: firstname.lastname@example.org
call us: (207) 576-4173
Philadelphia Museum of Art
The Philadelphia Museum of Art sits majestically on a rise at the end of the Benjamin Franklin Parkway. The vast collections of this temple of art make it the third-largest art museum in the country, and an absolute must-see on the city's cultural circuit.
Among its impressive holdings in Renaissance, American, Impressionist and Modern art, some standouts include a great Rogier van der Weyden altarpiece, a large Bathers by Cezanne, a room devoted to Philadelphia's own Thomas Eakins, and Marcel Duchamp's notorious mixed-media Bride Stripped Bare by her Bachelors (The Large Glass), exactly as the dada master installed it.
Valley Forge National Historical Park
With more than 3,600 acres of rolling hills and well-worn trails, Valley Forge is now a magnet for runners, bicyclists and picnickers as well as history buffs.
The vast expanse of open space links the Schuylkill River Trail to the Horse Shoe Trail, turning the park into a major hub in a 75-mile system linking Philadelphia to the Appalachian Trail.
The Liberty Bell Center
The Liberty Bell has a new home, and it is as powerful and dramatic as the Bell itself. Throughout the expansive, light-filled Center, larger-than-life historic documents and graphic images explore the facts and the myths surrounding the Bell.
National Constitution Center
The 160,000-square-foot National Constitution Center explores and explains this amazing document through high-tech exhibits, artifacts, and interactive displays. The Kimmel Theater, a 350-seat star-shaped theater, features “Freedom Rising,” a multimedia production combining film, a live actor and video projection on a 360° screen to tell the stirring story of “We the people.”
The Franklin Institute
An innovator in designing hands-on exhibits before “interactive” became a buzzword, The Franklin Institute is as clever as its namesake. Its eminently touchable attractions explore science in disciplines ranging from sports to space.
Highlights include The Sports Challenge, which uses virtual-reality technology to illustrate the physics of sports; The Train Factory's climb-aboard steam engine; Space Command's simulated earth-orbit research station; a fully equipped weather station; and exhibits on electricity.
The Barnes Foundation
The Barnes Foundation was created in 1922, a school originating with Barnes’ educational experimentation in his Argyrol (pharmaceutical) factory. Barnes and The Foundation’s first director of education, John Dewey, were interested in fostering cognitive development through new approaches to education, and in heightening critical-thinking and problem-solving skills through the study of art. Barnes, like Dewey, was actively engaged in development of an intellectual framework and educational philosophies and practices with many of the best artists and thinkers of his day.
The Rocky Statue
One of Philadelphia’s most famous pieces of public art is a bigger-than-life boxer… literally. Originally created for Rocky III, the sculpture is now a real-life monument to a celluloid hero. The fictional Rocky Balboa of Sylvester Stallone’s Rocky movies was immortalized in bronze in 1980. After filming for the movie completed, Stallone donated the statue to the City of Philadelphia.
Franklin Square, one of Philadelphia’s five original public squares laid out by William Penn in his original plan for the city, has undergone a dramatic renovation. The park now boasts several family-friendly attractions, including a miniature golf course, classic carousel, burger joint, storytelling bench, picnic area and more.